LSCP Laserscope (MM)

Laserscope Reports Additional FDA Clearances for Its New Gemini Product FDA Clears Gemini Laser System for Acne Treatment, Permanent Hair Reduction, and Wrinkle Reduction SAN JOSE, Calif., April 6 /PRNewswire-FirstCall/ -- Laserscope , a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that the Food and Drug Administration (FDA) has cleared Laserscope's Gemini(TM) laser system for three major additional indications, including acne treatment, permanent hair reduction, and wrinkle reduction. Including these new clearances, Laserscope's Gemini laser system is FDA-cleared to perform 21 total procedures. "We are very pleased and excited with this news, and believe the three new FDA clearances validate the tremendous versatility of the Gemini product platform," said Eric Reuter, Laserscope's President and Chief Executive Officer. "Using the Gemini, a physician can now perform over 90% of all aesthetic laser procedures currently available in the physician's office." "Because of its versatility, we believe the Gemini will have significant appeal to those physicians who prefer to use a single product platform rather than several different and disparate laser systems," continued Reuter. "This is especially important and appealing in the so-called 'non-traditional' aesthetic market segment which includes physicians such as gynecologists, family practitioners, and other physicians who are seeking additional fee-for-service revenue streams such as those offered by cosmetic laser procedures. These physicians typically do not have space or finances to purchase several laser systems and would prefer to devote only a single treatment room in which to perform cosmetic treatments." About the Gemini The Gemini laser system combines, via an intuitive touch-screen display, two of the most versatile and clinically proven laser wavelengths, 532 nanometers and 1064 nanometers, in one powerful system with two easily selectable, ergonomically designed treatment handpieces. The innovative, continuously adjustable Versastat handpiece allows for the physician to choose up to 42 different spot sizes, enabling very precise treatment control of isolated vascularities and/or pigmentation areas. Unlike Intense Pulse Light (IPL) and some other laser sources which are typically only available in a single spot or several discrete spot sizes and are often heavy, bulky and difficult to use around certain areas of the body, the Gemini's treatment flexibility allows for precise treatment control around the face, nose, and other contoured areas as well as large treatment areas. The Gemini is additionally complemented by a large spot handpiece which allows for fast laser coverage of large areas, making treatments for Acne, Skin Rejuvenation and Hair Removal less tedious and more cost-effective for the physician. Additionally, the Gemini incorporates the same continuous contact cooling technology as the Aura and Lyra lasers to aid in physician and patient safety and comfort. The Gemini's technology platform is based in part on the GreenLight PV(TM) surgical laser system which was released in early 2002 and is being used in many areas of the world for the pioneering new treatment alternative for Benign Prostatic Hyperplasia (BPH) called Photoselective Vaporization of the Prostate (PVP(TM)). About Laserscope Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company's web site at http://www.laserscope.com/. Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. These risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent forms 10-Q areavailable upon request from its Investor Relations Department. For further information please contact: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Tricia Ross, Analysts, or Laurie Berman, General Inquiries, both of Financial Relations Board, +1-310-407-6555, for Laserscope DATASOURCE: Laserscope CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Tricia Ross, Analysts, or Laurie Berman, General Inquiries, both of Financial Relations Board, +1-310-407-6555, for Laserscope Web site: http://www.laserscope.com/

Copyright